NCT03194893 2026-02-20A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerHoffmann-La RochePhase 3 Active not recruiting200 enrolled
NCT03780517 2023-10-30Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered TumorsBoston PharmaceuticalsPhase 1 Completed117 enrolled
NCT03154086 2019-08-09A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy VolunteersGlaxoSmithKlinePhase 1 Completed68 enrolled 80 charts
NCT02727283 2017-05-08A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy VolunteersGlaxoSmithKlinePhase 1 Completed16 enrolled